Pursuing Innovation In A Changing China
This article was originally published in PharmAsia News
Pharmaceutical companies in China have no doubt felt the chill over the past two years from authorities’ eagerness to reshape the industry with stricter regulations and compliance requirements. But does China have the framework in place to encourage innovation?
You may also be interested in...
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma